Intensity Therapeutics, Inc.
INTS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.00 | 0.17 |
| FCF Yield | -22.85% | -42.40% | -6.65% | -10.36% |
| EV / EBITDA | -1.28 | -1.46 | -8.57 | -7.34 |
| Quality | ||||
| ROIC | -37.23% | -115.65% | -687.04% | -103.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.89 | 0.97 | 0.59 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 2.81% | -23.48% | 25.45% | 32.83% |
| Safety | ||||
| Net Debt / EBITDA | 2.54 | 0.83 | 0.24 | 0.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -15,338.57 | -23,790.00 | -9,142.50 |